Cognition Therapeutics (CGTX)

Company Profile

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/

Company profile

Ticker

CGTX

Exchange

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

Former names

COGNITION THERAPUTICS INC

SEC CIK

0001455365

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Cognition Therapeutics PTY LTD ...

CGTX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

EFFECT

Notice of effectiveness

4 Jan 23

8-K

Entry into a Material Definitive Agreement

Developing disease - modifying medicines for degenerative disorders November 2022

14 Nov 22

Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 22

424B4

Prospectus supplement with pricing info

14 Nov 22

EFFECT

Notice of effectiveness

Correspondence with SEC

7 Nov 22

Transcripts

CGTX

Earnings call transcript

2021 Q4

30 Mar 22

Latest ownership filings

View all

SC 13D/A

BIOS Memory SPV I, LP

Financial summary

Financial statements Chart CGTX financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	46.61 mm	46.61 mm	46.61 mm	46.61 mm	46.61 mm	46.61 mm
Cash burn (monthly)	(no burn)	(no burn)	4.21 mm	3.84 mm	18.33 k	221.42 k
Cash used (since last report)	n/a	n/a	17.23 mm	15.71 mm	75.04 k	906.28 k
Cash remaining	n/a	n/a	29.38 mm	30.90 mm	46.53 mm	45.70 mm
Runway (months of cash)	n/a	n/a	7.0	8.1	2538.3	206.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

CGTX institutional ownership history Ownership history

31.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	31	30	+3.3%
Opened positions	6	7	-14.3%
Closed positions	5	5	–
Increased positions	7	10	-30.0%
Reduced positions	7	6	+16.7%

13F shares	Current	Prev Q	Change
Total value	26.87 mm	28.77 mm	-6.6%
Total shares	8.99 mm	9.15 mm	-1.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BIOS Memory SPV I	3.91 mm	$17.22 mm	0.0%
Pathstone Family Office	2.21 mm	$4.20 mm	0.0%
AIGH Capital Management	798.34 k	$1.52 mm	-12.3%
Vanguard	401.20 k	$762.00 k	+465.7%
Voss Capital	219.10 k	$416.00 k	-29.2%
Commonwealth Equity Services	219.07 k	$416.00 k	+1.9%
AFG American Financial	205.00 k	$389.00 k	0.0%
Worth Venture Partners	200.19 k	$380.00 k	-12.3%
P.a.w. Capital	100.00 k	$190.00 k	-25.9%
Carlson Capital L P	100.00 k	$190.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Vanguard	401.20 k	+330.28 k	+465.7%
Nantahala Capital Management	0.00	-192.75 k	EXIT
Prosight Management	0.00	-120.20 k	EXIT
AIGH Capital Management	798.34 k	-112.46 k	-12.3%
Carlson Capital L P	100.00 k	+100.00 k	NEW
Voss Capital	219.10 k	-90.37 k	-29.2%
Perigon Wealth Management	36.90 k	-85.95 k	-70.0%
Geode Capital Management	80.41 k	+65.24 k	+430.0%
Captrust Financial Advisors	50.00 k	+50.00 k	NEW
Frontier Wealth Management	0.00	-50.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CGTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Nov 22	Richstone Ellen B	Common Stock	Buy	Acquire P	No	No	2.655	10,000	26.55 k	10,000
28 Nov 22	Leslie W. Kreis	Common Stock	Buy	Acquire P	Yes	No	2.6497	1,871	4.96 k	309,748
28 Nov 22	Leslie W. Kreis	Common Stock	Buy	Acquire P	Yes	No	2.6497	12,220	32.38 k	2,021,906
28 Nov 22	Leslie W. Kreis	Common Stock	Buy	Acquire P	Yes	No	2.6497	1,973	5.23 k	326,733
28 Nov 22	Fletcher Aaron G.L.	Common Stock	Buy	Acquire P	Yes	No	2.6497	1,871	4.96 k	309,748
28 Nov 22	Fletcher Aaron G.L.	Common Stock	Buy	Acquire P	Yes	No	2.6497	12,220	32.38 k	2,021,906
28 Nov 22	Fletcher Aaron G.L.	Common Stock	Buy	Acquire P	Yes	No	2.6497	1,973	5.23 k	326,733
16 Nov 22	Fletcher Aaron G.L.	Common Stock	Buy	Acquire P	Yes	No	1.4	8,269	11.58 k	307,877
16 Nov 22	Fletcher Aaron G.L.	Common Stock	Buy	Acquire P	Yes	No	1.4	54,009	75.61 k	2,009,686
16 Nov 22	Fletcher Aaron G.L.	Common Stock	Buy	Acquire P	Yes	No	1.4	8,722	12.21 k	324,760